文献速递心力衰竭与心肌病

心力衰竭严重程度对Vutrisiran在转甲状腺素蛋白淀粉样变心肌病中疗效的影响

Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis With Cardiomyopathy.
PubMed 文献 · J Am Coll Cardiol · 2025-03-17

HELIOS-B试验的探索性亚组分析显示,在ATTR-CM患者中,Vutrisiran相比安慰剂在不同基线心力衰竭严重程度亚组中均观察到降低全因死亡和复发性心血管事件风险的证据,且在较早、较轻的疾病阶段获益最大。

要点

  • Vutrisiran在NYHA I-III级各亚组中均显示获益趋势,早期轻度疾病获益更明显。
  • NT-proBNP较低三分位组和NAC 1期患者中Vutrisiran获益更显著。
  • 单药治疗人群及多个功能/生物标志物终点中观察到相似效果。

核心结论

  • Vutrisiran在HELIOS-B的基线疾病严重程度范围内均显示获益证据,在较早、较轻的疾病中获益最大。

研究设计与样本

  • HELIOS-B随机、双盲、安慰剂对照试验的探索性亚组分析,纳入654例ATTR-CM患者,按1:1随机接受Vutrisiran 25 mg或安慰剂每3个月一次,最长36个月。
  • 纳入NYHA功能I-III级患者,排除IV级或III级伴NAC 3期者。

主要发现

  • 全因死亡和复发性心血管事件复合终点:NYHA I、II、III级HR分别为0.54(95%CI 0.27-1.10)、0.77(95%CI 0.57-1.03)、0.68(95%CI 0.33-1.41)。
  • NT-proBNP三分位<1,368 ng/L、≥1,368且<2,691 ng/L、≥2,691 ng/L的HR分别为0.52(95%CI 0.30-0.88)、0.61(95%CI 0.37-1.00)、0.93(95%CI 0.64-1.35)。
  • NAC 1期和2/3期的HR分别为0.49(95%CI 0.34-0.72)和1.08(95%CI 0.74-1.56)。
  • Columbia早期和中/晚期HR分别为0.69(95%CI 0.45-1.07)和0.74(95%CI 0.53-1.02)。
  • 单药治疗人群及额外终点中观察到相似效果。

临床怎么用

  • 对于ATTR-CM患者,Vutrisiran在不同心衰严重程度中均可考虑使用,但应优先在疾病较早、较轻阶段启动以最大化获益。

局限性

  • 亚组分析为探索性,各亚组样本量较小且置信区间较宽,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vutrisiran reduced the risk of all-cause mortality (ACM) and recurrent cardiovascular (CV) events in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in HELIOS-B (A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy; NCT04153149). OBJECTIVES: This study sought to assess the effect of vutrisiran in HELIOS-B patients with different heart failure severities. METHODS: HELIOS-B randomized patients with ATTR-CM with NYHA functional class I-III (functional class IV or functional class III with National Amyloidosis Centre [NAC] stage 3 were excluded) 1:1 to vutrisiran 25 mg or placebo every 3 months for up to 36 months. This exploratory subgroup analysis assessed the primary composite endpoint of ACM and recurrent CV events, ACM, and additional functional and biomarker endpoints. RESULTS: Of 654 patients, 84 (13%), 508 (78%), and 62 (9%) were in NYHA functional class I, II, and III, respectively. Median baseline N-terminal pro-B-type natriuretic peptide (NT-proBNP) level was 1,920 ng/L. Lower risk of ACM and recurrent CV events was observed with vutrisiran vs placebo across baseline severity subgroups: respective HRs were 0.54 (95% CI: 0.27-1.10), 0.77 (95% CI: 0.57-1.03), and 0.68 (95% CI: 0.33-1.41) in NYHA functional classes I, II, and III, respectively; 0.52 (95% CI: 0.30-0.88), 0.61 (95% CI: 0.37-1.00), and 0.93 (95% CI: 0.64-1.35) in NT-proBNP tertiles <1,368 ng/L, ≥1,368 and <2,691 ng/L, and ≥2,691 ng/L; 0.49 (95% CI: 0.34-0.72) and 1.08 (95% CI: 0.74-1.56) in NAC stages 1 and 2/3, respectively; and 0.69 (95% CI: 0.45-1.07) and 0.74 (95% CI: 0.53-1.02) in Columbia early and intermediate/late stages, respectively. Similar effects were observed in the monotherapy population (patients not on tafamidis at baseline) and across the additional endpoints evaluated. CONCLUSIONS: Vutrisiran demonstrated evidence of benefit across the range of baseline disease severities in HELIOS-B, with the greatest benefit in earlier, less severe disease. (A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy [HELIOS-B]; NCT04153149).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Maurer, Witteles, Garcia-Pavia, et al. Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis With Cardiomyopathy. J Am Coll Cardiol. 2025. PMID: 40099776. doi:10.1016/j.jacc.2025.03.477

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。